FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
-
28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study Miriam Forte1, Francesco Caraglia1, Silvana Cozzolino1, Antonino Colloca1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Francesca Sparano5, Maria Chiara Sergi3, Teresa Del Giudice4, Immacolata Paciolla6, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi6, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples; 2Department of Clinical Medicine and Surgery, Federico Il University, Naples; 3Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli", Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Napoli; 6Medical Oncology Unit AORN "San Pio", Benevento, Italy.
462 -
61 | SUNITINIB-INDUCED FOLLICULAR OCCLUSION DISORDER OF THE FACE: A CASE REPORT Z. Fratton1|2, A. Bolzon2|3, A. Corrà2, G. Frattin2|3, L. Germi2, L. Gnesotto2, D. Lai2, G. Mioso2, E. Pezzolo2, L. Schiesari2 | 1Department of Medicine, Institute of Dermatology, University of Udine, Italy; 2Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy; 3Unit of Dermatology, Department of Medicine, University of Padova, Italy
218PDF: 147 -
11 | EFFICACY AND SAFETY OF LEBRIKIZUMAB IS MAINTAINED UP TO 4 YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: FIRST YEAR OF ADLONG LONG-TERM EXTENSION TRIAL L. Stingeni1, S. Weidinger2, A. Irvine3, D. Thaçi4, J. Szepietowski5, T. Biedermann6, H. Agell7, Y. Mihaylov7, B. Kostov7, R. Coll7, W. Romero8, K. Reich9 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 3Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 4Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 5Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wrocław University of Science and Technology, Wrocław, Poland; 6Department of Dermatology and Allergy, Technical University of Munich, School of Medicine and Health, Munich, Germany; 7Almirall S.A., Barcelona, Spain; 8Eli Lilly and Company, Indianapolis, IN, USA; 9Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
141PDF: 85 -
Pilot study of topical management of folliculitis: clinical outcomes and safety in routine practice
309PDF: 219SUPPLEMENTARY MATERIAL: 33

